A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

PHASE3CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

April 3, 2023

Study Completion Date

April 21, 2023

Conditions
Chemotherapy Induced Anemia
Interventions
DRUG

SEPO®

SEPO® will be administered per dose and schedule specified in the arm description.

DRUG

Roxadustat

Roxadustat will be administered per dose and schedule specified in the arm description.

Trial Locations (45)

Unknown

Affiliated Hospital of Hebei University, Baoding

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Capital Medical University Chest Hospital, Beijing

Peking University Cancer Hospital, Beijing

Jilin Cancer Hospital, Changchun

Hunan Cancer Hospital, Changsha

Sichuan Cancer Hospital, Chengdu

Chongqing Bishan People's Hospital, Chongqing

The Second Affiliated Hospital of Third Military Medical University (Xinqiao Hospital), Chongqing

Deyang People's Hospital, Deyang

The First People's Hospital of Foshan, Foshan

Fujian Medical University Union Hospital, Fuzhou

Sun Yat-sen Memorial Hospital, Sun Yat-sen University - Gynecologic Oncology Department, Guangzhou

Sun Yat-sen Memorial Hospital, Sun Yat-sen University - Oncology Department, Guangzhou

Hangzhou Cancer Hospital, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

Harbin Medical University Cancer Hospital, Harbin

Anhui Cancer Hospital, Hefei

Jiangxi Cancer Hospital, Jiangxi

Shandong First Medical University Cancer Hospital, Jinan

The Second Hospital of Lanzhou University, Lanzhou

Jiangsu Province Hospital, Nanjing

The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning

Neijiang Second People's Hospital, Neijiang

Ningbo First Hospital, Ningbo

Jiangxi Pingxiang People's Hospital, Pingxiang

The Affiliated Hospital of Qingdao University, Qingdao

Fudan University Shanghai Cancer Center, Shanghai

Shanghai Chest Hospital, Shanghai

Shanghai Fifth People's Hospital, Shanghai

Liaoning Cancer Hospital & Institute, Shenyang

The First Hospital of China Medical University - Oncology Department Breast Cancer Group, Shenyang

The First Hospital of China Medical University - Oncology Department Lung Cancer Group, Shenyang

Peking University Shenzhen Hospital, Shenzhen

Shanxi Cancer Hospital, Taiyuan

Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan

University of Science and Technology, Wuhan

Wuhan Fourth Hospital, Wuhan

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Cancer Hospital of Xinjiang Medical University, Xinjiang

Xuzhou Central Hospital, Xuzhou

Yantai Yuhuangding Hospital, Yantai

General Hospital of Ningxia Medical University, Yinchuan

Henan Cancer Hospital, Zhengzhou

Zhuzhou Central Hospital, Zhuzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

FibroGen

INDUSTRY